Co-Diagnostics, Inc.
CODX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $7 | $34 | $98 |
| % Growth | -42.5% | -80.1% | -65% | – |
| Cost of Goods Sold | $1 | $4 | $5 | $12 |
| Gross Profit | $3 | $3 | $29 | $86 |
| % Margin | 74.5% | 38.6% | 84% | 88.2% |
| R&D Expenses | $21 | $23 | $17 | $15 |
| G&A Expenses | $16 | $14 | $14 | $12 |
| SG&A Expenses | $21 | $21 | $22 | $25 |
| Sales & Mktg Exp. | $4 | $7 | $7 | $13 |
| Other Operating Expenses | $1 | $1 | $17 | $0 |
| Operating Expenses | $43 | $45 | $56 | $40 |
| Operating Income | -$40 | -$43 | -$27 | $46 |
| % Margin | -1,023.7% | -626.9% | -78.8% | 47.1% |
| Other Income/Exp. Net | $2 | $5 | $8 | -$0 |
| Pre-Tax Income | -$38 | -$38 | -$19 | $46 |
| Tax Expense | $0 | -$3 | -$5 | $9 |
| Net Income | -$38 | -$35 | -$14 | $37 |
| % Margin | -961.4% | -518.7% | -41.6% | 37.5% |
| EPS | -1.24 | -1.2 | -0.45 | 1.27 |
| % Growth | -3.3% | -166.7% | -135.4% | – |
| EPS Diluted | -1.24 | -1.2 | -0.45 | 1.23 |
| Weighted Avg Shares Out | 30 | 29 | 31 | 29 |
| Weighted Avg Shares Out Dil | 30 | 29 | 31 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$39 | -$41 | -$10 | $46 |
| % Margin | -988.6% | -608.9% | -30.1% | 47.4% |